XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Summarized fair values of assets acquired and liabilities assumed
The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:
(in millions)Amount
Cash and cash equivalents$726 
Inventories946 
Intangible assets
Finite-lived intangible asset4,600 
Acquired IPR&D15,760 
Outlicense contract175 
Deferred income taxes(4,565)
Liability related to future royalties(1,100)
Other assets (and liabilities), net64 
Total identifiable net assets16,606 
Goodwill3,991 
Total consideration transferred$20,597 
Supplemental pro forma information
The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:
Year Ended December 31
(in millions, unaudited)20202019
Total revenues$24,778 $22,449 
Net income (loss) attributable to Gilead$(323)$4,488